Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease

GlycoNex submits marketing authorisation application for denosumab biosimilar to Japanese regulator

Antengene reports first patient dosed in Phase I study of ATG-201 in B cell-mediated autoimmune diseases

Akeso publishes ivonescimab Phase II study results in Nature Medicine

Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment

First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer

SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA

Circular Genomics and PharmatrophiX collaborate on advancing circRNA biomarkers in neurodegenerative drug development

Minghui Pharmaceutical licenses IGF-1R antibody to ASKA Pharmaceutical in Japan

WuXi Biologics receives two awards at 2026 HERA

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

Agilent acquires Proscia for USD240m

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

Sectra wins seven-year radiology reporting contract with Mount Sinai Health System

Pentixapharm advances preparationsfor Phase 3 PANDA study